FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

August 5, 2022
Focus: Esophageal Cancer
Topics: Treatment Options

The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.